Merck (ETR:MRK) Stock Upgrade
Joh. Berenberg Gossler & Co. KG upgraded shares of Merck (ETR:MRK) to a solid “Buy” rating in an interesting research report published on Saturday morning. Analysts currently have a EUR 103.00 target set on the stock. This target would suggest a possible upside of 11.40% from the last stock close of the stock.
From a total of 18 analysts covering Merck (ETR:MRK) stock, 8 rate it a ”Buy”, 0 a “Sell”, and 11 a ”Hold”. This means that 42% of the ratings are positive. The highest target price is €72 while the lowest target price is €54. The mean of all analyst targets is €62.56 with a 5.97% above today’s (€92.49) stock price. Merck was the topic of 25 analyst reports since August 4, 2015 according to the firm StockzIntelligence Inc. Landesbank upgraded shares on December 3 to “Buy” rating. UBS maintained shares with “Neutral” rating and €89 target share price in a report from a November 11. Deutsche Bank upgraded MRK stock in a recent report from November 28 to “Buy” rating. BNP Paribas upgraded the rating on October 22. BNP Paribas has a “Outperform” rating and a €107 price target on shares. Finally, S&P Research maintained the stock with “Hold” rating in a report issued on a November 13.
The stock decreased 1.33% or EUR 1.25 on December 4, striking EUR 92.49. Approximately 661,507 shares of stock traded hands or 21.80% up from the average. Merck KGaA (ETR:MRK) has declined 11.54% since May 4, 2015 and is downtrending. It has underperformed by 8.76% the S&P500.
Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The company has a market cap of 11.95 billion EUR. The Firm diversifies its activities into four business divisions: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. It has 31.69 P/E ratio. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnological origin.
According to Zacks Investment Research, “Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.” Get a free copy of the Zacks research report on Merck KGaA (MRK).